Free biotech catalyst calendar
Each date comes with the SEC sentence it came from. Open a line to see the sentence and how its wording has changed.Each date comes with its SEC sentence.
250 programs as of
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
These records could not be loaded. Open a numbered page to read the original quotations and SEC links.
Window ends in: 2026
Grouped by the period end. The company's wording is retained in each row; no countdown is shown.
Period the company stated: 2026
clinical trial in 2026Details
Tango Therapeutics, Inc. (TNGX) · vopimetostat
Stage: Not stated
Public float (as of ): $528M (SEC filing) · $500M–$2B
Period the company stated: 2026
disclose clinical data in the lung cancer cohort of the vopimetostat monotherapy clinical trial in 2026
Earlier SEC statements (4)
- · “Disclose vopimetostat lung cancer monotherapy data in 2H 2026” · SEC filing
- · “we anticipate providing a safety and efficacy update in 2026.” · SEC filing
- · “we anticipate providing a safety and efficacy update in 2026.” · SEC filing
- · “we anticipate providing a safety and efficacy update in 2026.” · SEC filing
Period the company stated: by year-end 2026
period of the study by year-end 2026.Details
Entrada Therapeutics, Inc. (TRDA) · ENTR-601-44
Stage: Not stated
Public float (as of ): $191M (SEC filing) · Under $500M
Period the company stated: by year-end 2026
The Company is on track to report data from the Cohort 1 (6 mg/kg) open-label period of the study by year-end 2026.
Period the company stated: year-end 2026
These data are expected by year-end 2026.Details
Zenas BioPharma, Inc. (ZBIO) · ZB021
Stage: Not stated
Public float (as of ): $259M (SEC filing) · Under $500M
Period the company stated: year-end 2026
These data are expected by year-end 2026.
Earlier SEC statements (1)
- · “These data are expected by year-end 2026.” · SEC filing
Window ends in: 2027
Grouped by the period end. The company's wording is retained in each row; no countdown is shown.
Period the company stated: 2H:2026 or 1H:2027
data from this trial in 2H:2026 or 1H:2027.Details
Actinium Pharmaceuticals, Inc. (ATNM) · Actimab-A + PD-1 inhibitor
Stage: Not stated
Public float (as of ): $43M (SEC filing) · Under $500M
Period the company stated: 2H:2026 or 1H:2027
We expect to report initial data from this trial in 2H:2026 or 1H:2027.
Period the company stated: 1H27 & 2H27
Clinical Data Expected 1H27 & 2H27Details
Adicet Bio, Inc. (ACET) · ADI-212
Stage: Not stated
Public float (as of ): $50M (SEC filing) · Under $500M
Period the company stated: 1H27 & 2H27
Clinical Data Expected 1H27 & 2H27
Earlier SEC statements (2)
- · “Subject to regulatory clearance to proceed with a clinical trial, we expect to report initial clinical data from this program in the second half of 2026.” · SEC filing
- · “Subject to regulatory clearance to proceed with a clinical trial, we expect to report initial clinical data from this program in the second half of 2026.” · SEC filing
Period the company stated: 2027
Data Expected in 2027Details
Alkermes plc. (ALKS) · ALKS 7290
Stage: Phase 2SEC filing · “Phase 2”
Public float (as of ): $4.6B (SEC filing) · Over $2B
Period the company stated: 2027
Phase 2 Study of ALKS 7290 in Adults With ADHD is Enrolling, Data Expected in 2027
ClinicalTrials.gov NCT07755410 · NCT stated in SEC filing
Period the company stated: 2027
in shift work disorder (2027)Details
Axsome Therapeutics, Inc. (AXSM) · solriamfetol
Stage: Phase 3SEC filing · “Phase 3; Phase 3”
Public float (as of ): $4.4B (SEC filing) · Over $2B
Period the company stated: 2027
Clinical Trial Topline Results: o Phase 3 ENGAGE trial of solriamfetol in binge eating disorder (4Q 2026) o Phase 3 SUSTAIN trial of solriamfetol in shift work disorder (2027)
Period the company stated: 2027
a data update expected in 2027.Details
BIOMARIN PHARMACEUTICAL INC (BMRN) · BMN 333
Stage: OtherSEC filing · “Phase 2/3”
Public float (as of ): $6.7B (SEC filing) · Over $2B
Period the company stated: 2027
The Phase 2/3 study is enrolling, with a data update expected in 2027.
Earlier SEC statements (1)
- · “A data update from this study is expected in 2027.” · SEC filing
Period the company stated: 2027
disease are anticipated in 2027.Details
COGNITION THERAPEUTICS INC (CGTX) · CT1812
Stage: Phase 2SEC filing · “Phase 2”
Public float (as of ): $18M (SEC filing) · Under $500M
Period the company stated: 2027
Topline results from the 545-participant Phase 2 ‘START’ COG0203 (NCT05531656) study in mild cognitive impairment (MCI) and early Alzheimer's disease are anticipated in 2027.
ClinicalTrials.gov NCT05531656 · NCT stated in SEC filing
Period the company stated: 2027
results are expected in 2027.Details
Dare Bioscience, Inc. (DARE) · DARE-HPV
Stage: Not stated
Public float (as of ): $21M (SEC filing) · Under $500M
Period the company stated: 2027
Topline results are expected in 2027.
Period the company stated: 2027
data from the study in 2027.Details
Dare Bioscience, Inc. (DARE) · Ovaprene
Stage: Not stated
Public float (as of ): $21M (SEC filing) · Under $500M
Period the company stated: 2027
We currently expect to report topline data from the study in 2027.
- DCTHDelcath Systems · melphalan for injection / Hepatic Delivery SystemTopline/data readout MatchedSEC ↗Watch
Period the company stated: by the end of 2027
is anticipated to read out by the end of 2027, while OS, a secondary endpoint, is expected inDetails
DELCATH SYSTEMS, INC. (DCTH) · melphalan for injection / Hepatic Delivery System
Stage: Not stated
Public float (as of ): $419M (SEC filing) · Under $500M
Period the company stated: by the end of 2027
The trial’s primary endpoint, hPFS, is anticipated to read out by the end of 2027, while OS, a secondary endpoint, is expected in 2028.
Period the company stated: 2027
results from the study in 2027Details
Denali Therapeutics Inc. (DNLI) · DNL593
Stage: Not stated
Public float (as of ): $1.1B (SEC filing) · $500M–$2B
Period the company stated: 2027
Denali now expects results from the study in 2027
Earlier SEC statements (6)
- · “Phase 1/2 study of DNL593, including biomarker results, are expected by the end of 2026” · SEC filing
- · “FTD- GRN and expects results by the end of 2026” · SEC filing
- · “FTD- GRN , and results are expected by the end of 2026” · SEC filing
- · “Phase 1/2 study of DNL593, including biomarker results, are expected by the end of 2026” · SEC filing
- · “Initial FTD- GRN patient data are expected in 2026” · SEC filing
- · “Initial FTD- GRN patient data are expected in 2026” · SEC filing
Period the company stated: 2027
disease are expected in 2027Details
Denali Therapeutics Inc. (DNLI) · DNL921
Stage: Phase 1SEC filing · “Phase 1/1b”
Public float (as of ): $1.1B (SEC filing) · $500M–$2B
Period the company stated: 2027
clinical proof-of-concept data from the ongoing Phase 1/1b study of DNL921 in healthy volunteers and participants with Alzheimer's disease are expected in 2027
Period the company stated: 2027
data are expected in 2027Details
Denali Therapeutics Inc. (DNLI) · DNL952
Stage: Not stated
Public float (as of ): $1.1B (SEC filing) · $500M–$2B
Period the company stated: 2027
initial clinical data are expected in 2027
Period the company stated: 2027
syndrome type A in 2027.Details
Denali Therapeutics Inc. (DNLI) · zafinofusp alfa / DNL126
Stage: Not stated
Public float (as of ): $1.1B (SEC filing) · $500M–$2B
Period the company stated: 2027
Denali expects a Biologics License Application (BLA) submission and potential accelerated approval for zafinofusp alfa for Sanfilippo syndrome type A in 2027.
Earlier SEC statements (1)
- · “Denali expects a Biologics License Application (BLA) submission and potential accelerated approval for DNL126 for Sanfilippo syndrome type A in 2027.” · SEC filing
Period the company stated: 2027
topline data expected in 2027.Details
ENANTA PHARMACEUTICALS INC (ENTA) · zelicapavir
Stage: Not stated
Public float (as of ): $110M (SEC filing) · Under $500M
Period the company stated: 2027
LOTUS is designed to evaluate the efficacy, safety, and antiviral activity of zelicapavir, with topline data expected in 2027.
Earlier SEC statements (2)
- · “Enanta also announced plans to initiate a Phase 2b clinical trial of zelicapavir in pediatric patients with RSV, with topline data expected in 2027.” · SEC filing
- · “with topline data expected in 2027” · SEC filing
Period the company stated: 2027
RESOLVE is expected in 2027.Details
ENANTA PHARMACEUTICALS INC (ENTA) · zelicapavir
Stage: Phase 2SEC filing · “Phase 2b”
Public float (as of ): $110M (SEC filing) · Under $500M
Period the company stated: 2027
Topline Phase 2b data from RESOLVE is expected in 2027.
Earlier SEC statements (2)
- · “The Phase 2b portion of the trial will confirm the treatment effect with topline data expected in 2027.” · SEC filing
- · “with data from the Phase 2b portion expected in 2027” · SEC filing
Period the company stated: 2027
submission is planned in 2027.Details
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) · lifileucel (AMTAGVI)
Stage: Not stated
Public float (as of ): $534M (SEC filing) · $500M–$2B
Period the company stated: 2027
A supplemental Biologics License Application (sBLA) submission is planned in 2027.
Period the company stated: 2027
OUTCOMES trial in 2027.Details
MADRIGAL PHARMACEUTICALS, INC. (MDGL) · resmetirom
Stage: Not stated
Public float (as of ): $5.6B (SEC filing) · Over $2B
Period the company stated: 2027
We expect results from the MAESTRO-NASH OUTCOMES trial in 2027.
Earlier SEC statements (1)
- · “We expect results from the MAESTRO-NASH OUTCOMES trial in 2027.” · SEC filing
Period the company stated: 2027
and expect topline data in 2027Details
Mirum Pharmaceuticals, Inc. (MIRM) · MRM-3379
Stage: Not stated
Public float (as of ): $2.3B (SEC filing) · Over $2B
Period the company stated: 2027
Fragile-X Syndrome (“FXS”) and expect topline data in 2027
Earlier SEC statements (4)
- · “Fragile-X Syndrome (“FXS”) and expect topline data in 2027” · SEC filing
- · “Fragile-X Syndrome (“FXS”) and expect topline data in 2027” · SEC filing
- · “BLOOM Phase 2 clinical study of MRM-3379 in FXS and expect topline data in 2027” · SEC filing
- · “top-line data from the Phase 3 Livmarli EXPAND clinical trial for the treatment of other ultra-rare cholestatic pruritus indications, the Phase 2b volixibat clinical trial for the treatment of primary biliary cholangitis and the Phase 2 clinical trial of MRM-3379 for the treatment of Fragile-X Syndrome in 2027” · SEC filing
Period the company stated: 2027
clinical milestones in 2027, including Phase 3 readouts for osavampator in major depressiveDetails
NEUROCRINE BIOSCIENCES INC (NBIX) · direclidine
Stage: Phase 3SEC filing · “Phase 3”
Public float (as of ): $9.5B (SEC filing) · Over $2B
Period the company stated: 2027
clinical milestones in 2027, including Phase 3 readouts for osavampator in major depressive disorder and direclidine in schizophrenia
Earlier SEC statements (1)
- · “Phase 3 clinical program for direclidine in schizophrenia (with initial topline data expected in 2027)” · SEC filing
Period the company stated: 2027
clinical milestones in 2027, including Phase 3 readouts for osavampator in major depressiveDetails
NEUROCRINE BIOSCIENCES INC (NBIX) · osavampator
Stage: Phase 3SEC filing · “Phase 3”
Public float (as of ): $9.5B (SEC filing) · Over $2B
Period the company stated: 2027
clinical milestones in 2027, including Phase 3 readouts for osavampator in major depressive disorder
Earlier SEC statements (1)
- · “Phase 3 clinical program for osavampator in MDD (with initial topline data expected in 2027)” · SEC filing
Period the company stated: 2027
to be available in 2027.Details
Nuvation Bio Inc. (NUVB) · safusidenib
Stage: Not stated
Public float (as of ): $496M (SEC filing) · Under $500M
Period the company stated: 2027
Data is anticipated to be available in 2027.
Period the company stated: 2027
Interim data is expected in 2027.Details
PLIANT THERAPEUTICS, INC. (PLRX) · PLN-101095 + pembrolizumab
Stage: Not stated
Public float (as of ): $69M (SEC filing) · Under $500M
Period the company stated: 2027
Interim data is expected in 2027.
Earlier SEC statements (2)
- · “Enrollment is underway with interim data expected in 2027.” · SEC filing
- · “Enrollment is underway with interim data expected in 2027.” · SEC filing
Period the company stated: 2027
topline results in 2027Details
Praxis Precision Medicines, Inc. (PRAX) · elsunersen
Stage: Phase 3SEC filing · “Phase 3”
Public float (as of ): $883M (SEC filing) · $500M–$2B
Period the company stated: 2027
EMBRAVE3, a Phase 3 registrational study for early-seizure-onset SCN2A DEE, and expect to announce topline results in 2027
Earlier SEC statements (3)
- · “EMBRAVE3 registrational trial, with topline results expected in 2027” · SEC filing
- · “topline results in 2027” · SEC filing
- · “topline results in 2027” · SEC filing
Period the company stated: 2027
NDA submission in 2027.Details
Praxis Precision Medicines, Inc. (PRAX) · relutrigine
Stage: Not stated
Public float (as of ): $883M (SEC filing) · $500M–$2B
Period the company stated: 2027
assuming successful initial NDA approval of relutrigine, the EMERALD study, if positive, would serve as the basis for a supplemental NDA submission in 2027.
Earlier SEC statements (3)
- · “Assuming successful initial NDA approval of relutrigine, the EMERALD study, if positive, would serve as the basis for a supplemental NDA submission in 2027.” · SEC filing
- · “Assuming approval of the NDA for relutrigine, we believe the EMERALD study, if positive, could serve as the basis for a supplemental NDA, or sNDA, submission in 2027.” · SEC filing
- · “Assuming successful initial NDA approval of relutrigine, the EMERALD study, if positive, would serve as the basis for a supplemental NDA submission in 2027.” · SEC filing
- RANIRani Therapeutics Holdings · RT-114 / PG-102 via RaniPill HCTopline/data readout MatchedSEC ↗Watch
Period the company stated: 2027
with data anticipated in 2027.Details
Rani Therapeutics Holdings, Inc. (RANI) · RT-114 / PG-102 via RaniPill HC
Stage: Not stated
Public float (as of ): $65M (SEC filing) · Under $500M
Period the company stated: 2027
The Phase 1b study will assess the safety, tolerability, and pharmacodynamic effect of eight weeks of repeat dosing with RT-114 in patients with obesity, and is expected to begin in 2026, with data anticipated in 2027.
Period the company stated: 2027
data expected in 2027.Details
Rapport Therapeutics, Inc. (RAPP) · RAP-219 long-acting injectable
Stage: Phase 1SEC filing · “Phase 1”
Public float (as of ): $275M (SEC filing) · Under $500M
Period the company stated: 2027
IND-enabling activities for RAP-219's long-acting injectable formulation continue, with initial Phase 1 pharmacokinetic data expected in 2027.
Earlier SEC statements (2)
- · “Development of RAP-219’s long-acting injectable formulation continues to advance, with IND-enabling activities underway and initial Phase 1 pharmacokinetic data expected in 2027.” · SEC filing
- · “Additionally, Rapport continues development of a long-acting injectable (LAI) formulation of RAP-219, with Phase 1 initial PK results expected in 2027.” · SEC filing
Period the company stated: 2027
trials in Graves’ disease 2027Details
Roivant Sciences Ltd. (ROIV) · IMVT-1402
Stage: Not stated
Public float (as of ): $9.8B (SEC filing) · Over $2B
Period the company stated: 2027
Topline data from potentially registrational trials in Graves’ disease 2027
Earlier SEC statements (5)
- · “Topline data from potentially registrational trials in Graves’ disease 2027” · SEC filing
- · “Topline data from the potentially registrational studies of IMVT-1402 in Graves’ disease are expected in calendar year 2027.” · SEC filing
- · “Topline data from potentially registrational trials in Graves’ disease 2027” · SEC filing
- · “Topline data from potentially registrational trials in Graves’ disease 2027” · SEC filing
- · “Topline data from potentially registrational trials in Graves’ disease 2027” · SEC filing
No program matches these filters. Ask for a company on the Watch page.
About this calendar
FDA dates and trial readouts as each company stated them, with SEC original links. 250 programs as of . Free, with no sign-in. No forecasts, prices or signals.
Add to Google Calendar Apple Calendar The subscription follows the filters chosen here. No sign-up; ORION stores nothing about subscribers.
How this calendar is made
- Entries are grouped by their retained period length: a date (with its count of days), a month (counted to its last day), then a quarter, half or year with no count. Period headings describe the window end; each row retains the company's exact wording. A date is the target action date the company stated.
- Company size is the public float (market value of shares held by non-affiliates) on the company’s latest cover, with its reference date and SEC link. It does not decide which programs are listed.
- Stage repeats the SEC filing or ClinicalTrials.gov registration wording. Without supporting wording, it is Not stated. Mixed phases retain their exact wording beside the source link.
- Medicine research links use an NCT number stated in the SEC filing or company announcement, or a ClinicalTrials.gov match with sponsor, medicine and phase evidence. A registry match is labelled “matched by ORION (not stated in the filing)”.
- Rows link to the program or company page. For a stated date, month, quarter, half or year, the period ends on its calendar end. Ambiguous qualifiers retain their wording without inferred endpoints.
- Ambiguous periods and events without a date retain the literal wording in a separate section. No calendar date or countdown is created; these records are excluded from calendar subscriptions.
- Active windows have no resolution filing held and end on or after today (UTC). A row with resolution evidence is shown in Results disclosed. Other rows move to Window ended after the stated period ends. Earlier wording and filing links remain available.
- Event types distinguish trial data, enrollment completion, site activation and event-based analysis. Financial results and FDA meetings have their own filters. Audit status remains in the SEC wording. The type follows the SEC wording.
- Displayed items need a true public-display field and a matching SEC quote and timing proof. Machine extraction does not add a founder review.
- “Wording changed” opens the earlier sentences, each with its date and filing.
- No forecast, price, score or signal. The calendar repeats what companies wrote.
Want an email when one of these changes? Get a free Watch.
Window ended
The company-stated period has ended. These records retain their wording and filing links.
1 programs as of
No ended windows match these filters.
Timing without a stated calendar date
These SEC statements retain an ambiguous period or an event trigger. No date or countdown is assigned.
3 records as of
No records match these filters. Choose All periods to view timing without a calendar date.
Results disclosed
An SEC resolution filing is held in these records. The original schedule, quote and source remain available.
47 programs as of
No disclosed records match these filters.